Establishment and Characterisation of Heterotopic Patient-Derived Xenografts for Glioblastoma

Establishment and Characterisation of Heterotopic Patient-Derived Xenografts for Glioblastoma

Glioblastoma is an aggressive brain tumour with a patient median survival of approximately 14 months. The development of innovative treatment strategies to increase the life span and quality of life of patients is hence essential. This requires the use of appropriate glioblastoma models for preclini...

Full description

Bibliographic Details
Main Authors: Sarah Meneceur, Annett Linge, Matthias Meinhardt, Sandra Hering, Steffen Löck, Rebecca Bütof, Dietmar Krex, Gabriele Schackert, Achim Temme, Michael Baumann, Mechthild Krause, Cläre von Neubeck
Format: Article
Language:English
Published: MDPI AG 2020-04-01
Series:Cancers
Subjects:
patient-derived xenografts
preclinical models
cancer stem cell markers
glioblastoma
growth data
Online Access:https://www.mdpi.com/2072-6694/12/4/871

Internet

https://www.mdpi.com/2072-6694/12/4/871

Similar Items